Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MYRIAD GENETICS INC
Report date March 01, 2023 · Filed March 02, 2023
Section 16 reporting ended · disclosed 2023-03-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 172,562 |
Reported balance
Holding disclosure · report date 2023-03-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 172,562 F1: The holdings for the Reporting Person include one additional share that was acquired on November 30, 2022 under the Myriad Genetics, Inc. 2012 Amended and Restated Employee Stock Purchase Plan, in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
Filing footnotes · ownership attribution and instrument terms
F1: The holdings for the Reporting Person include one additional share that was acquired on November 30, 2022 under the Myriad Genetics, Inc. 2012 Amended and Restated Employee Stock Purchase Plan, in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2022 Filed Oct 11, 2022 20:34 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 2,948 | $19.62 | $57,839.76 |
DisclosureSEC source: 0001628280-22-026251 · wf-form4_166552045769875.xml · nonDerivative · entry 2 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,561 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 7, 2022. Read SEC document |
| October 09, 2022 Filed Oct 11, 2022 20:34 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,978 | $19.62 | $38,808.36 |
DisclosureSEC source: 0001628280-22-026251 · wf-form4_166552045769875.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,509 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 7, 2022. Read SEC document |
| September 26, 2022 Filed Sep 27, 2022 20:30 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 2,216 | $18.41 | $40,796.56 |
DisclosureSEC source: 0001628280-22-025562 · wf-form4_166431062499276.xml · nonDerivative · entry 2 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,487 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 26, 2022. Read SEC document |
| September 25, 2022 Filed Sep 27, 2022 20:30 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,662 | $18.69 | $31,062.78 |
DisclosureSEC source: 0001628280-22-025562 · wf-form4_166431062499276.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,703 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 23, 2022. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 20:21 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,146 | $24.89 | $28,523.94 |
DisclosureSEC source: 0001628280-22-023765 · wf-form4_166154530195212.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,365 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 25, 2022. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:40 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 1,036 | $14.84 | $15,375.28 |
DisclosureSEC source: 0001519749-22-000010 · edgardoc.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,511 F1 · kind: These shares were acquired under the Myriad Genetics, Inc. 2012 Amended and Restated Employee Stock Purchase Plan, in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 24, 2022 Filed Mar 25, 2022 21:04 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 2,164 | $25.32 | $54,792.48 |
DisclosureSEC source: 0001519749-22-000008 · edgardoc.xml · nonDerivative · entry 2 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,475 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2022. Read SEC document |
| March 24, 2022 Filed Mar 25, 2022 21:04 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,477 | $25.32 | $37,397.64 |
DisclosureSEC source: 0001519749-22-000008 · edgardoc.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,639 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2022. Read SEC document |
| March 22, 2022 Filed Mar 23, 2022 20:57 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 19,238 | $0.00 | $0.00 |
DisclosureSEC source: 0001519749-22-000006 · edgardoc.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,116 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 21:55 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $23.98 | $0.00 |
DisclosureSEC source: 0001519749-22-000004 · edgardoc.xml · derivative · entry 6 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2022-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 21:55 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $23.98 | $0.00 |
DisclosureSEC source: 0001519749-22-000004 · edgardoc.xml · derivative · entry 5 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,500 shares Expires 2022-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 21:55 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 3,500 | $25.00 | $87,500.00 |
DisclosureSEC source: 0001519749-22-000004 · edgardoc.xml · nonDerivative · entry 4 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,878 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 21:55 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 3,500 | $23.98 | $83,930.00 |
DisclosureSEC source: 0001519749-22-000004 · edgardoc.xml · nonDerivative · entry 3 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 21:55 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 7,000 | $25.00 | $175,000.00 |
DisclosureSEC source: 0001519749-22-000004 · edgardoc.xml · nonDerivative · entry 2 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,878 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 21:55 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 7,000 | $23.98 | $167,860.00 |
DisclosureSEC source: 0001519749-22-000004 · edgardoc.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 22:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 19,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001519749-22-000002 · edgardoc.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,878 F1 · kind: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on March 24, 2021, subject to accomplishment of pre-determined performance metrics. On February 16, 2022, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on March 24, 2022, 25% on March 24, 2023, 25% on March 24, 2024, and 25% on March 24, 2025. Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 23:19 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 143 | $21.98 | $3,143.28 |
DisclosureSEC source: 0001519749-21-000019 · edgardoc.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,358 F1 · kind: These shares were acquired under the Myriad Genetics, Inc. 2012 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 09, 2021 Filed Oct 12, 2021 20:42 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 2,948 | $30.88 | $91,034.24 |
DisclosureSEC source: 0001519749-21-000017 · edgardoc.xml · nonDerivative · entry 2 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,215 F3 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock October 8, 2021. Read SEC document |
| October 09, 2021 Filed Oct 12, 2021 20:42 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,978 | $30.88 | $61,080.64 |
DisclosureSEC source: 0001519749-21-000017 · edgardoc.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,163 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 8, 2021. F2 · balance_after: Includes 41,021 shares of Myriad common stock that were omitted from the reporting person's Form 3, which was amended to reflect such shares on October 12, 2021. Read SEC document |
| September 26, 2021 Filed Sep 27, 2021 23:48 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 2,216 | $33.31 | $73,814.96 |
DisclosureSEC source: 0001519749-21-000015 · edgardoc.xml · nonDerivative · entry 2 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,120 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021. Read SEC document |
| September 25, 2021 Filed Sep 27, 2021 23:48 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 3,878 | $33.31 | $129,176.18 |
DisclosureSEC source: 0001519749-21-000015 · edgardoc.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,336 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 21:26 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 26,598 | $0.00 | $0.00 |
DisclosureSEC source: 0001519749-21-000013 · edgardoc.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,214 F1 · kind: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on October 8, 2020, subject to accomplishment of pre-determined performance metrics. On September 21, 2021, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 22:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 73,225 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001519749-21-000011 · edgardoc.xml · derivative · entry 6 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,225 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 22:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,775 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001519749-21-000011 · edgardoc.xml · derivative · entry 5 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,775 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 22:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 2,966 | $33.72 | $100,013.52 |
DisclosureSEC source: 0001519749-21-000011 · edgardoc.xml · nonDerivative · entry 4 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,616 F2 · kind: Represents the net exercise of outstanding stock options. The reporting person received 809 shares of common stock on net exercise of options to purchase 3,775 shares of common stock. The company withheld 2,966 shares of common stock for payment of the exercise price and tax withholdings, using the closing stock price on September 17, 2021 of $33.72. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 22:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 3,775 | $26.49 | $99,999.75 |
DisclosureSEC source: 0001519749-21-000011 · edgardoc.xml · nonDerivative · entry 3 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 22:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 64,480 | $33.72 | $2,174,265.60 |
DisclosureSEC source: 0001519749-21-000011 · edgardoc.xml · nonDerivative · entry 2 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,807 F1 · kind: Represents the net exercise of outstanding stock options. The reporting person received 8,745 shares of common stock on net exercise of options to purchase 73,225 shares of common stock. The company withheld 64,480 shares of common stock for payment of the exercise price and tax withholdings, using the closing stock price on September 17, 2021 of $33.72. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 22:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 73,225 | $26.49 | $1,939,730.25 |
DisclosureSEC source: 0001519749-21-000011 · edgardoc.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 01:58 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,148 | $34.81 | $39,961.88 |
DisclosureSEC source: 0001519749-21-000007 · edgardoc.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,062 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 25, 2021. Read SEC document |
| May 28, 2021 Filed Jun 3, 2021 22:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 1,082 | $15.86 | $17,161.60 |
DisclosureSEC source: 0001519749-21-000006 · edgardoc.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,210 F1 · kind: These shares were acquired under the Myriad Genetics, Inc. 2012 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 22:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 21,966 | $0.00 Strike: $24.89 | $0.00 |
DisclosureSEC source: 0001519749-21-000004 · edgardoc.xml · derivative · entry 9 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,966 shares Expires 2021-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 22:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 28,000 | $0.00 Strike: $19.47 | $0.00 |
DisclosureSEC source: 0001519749-21-000004 · edgardoc.xml · derivative · entry 8 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,000 shares Expires 2021-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 22:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 8,034 | $0.00 Strike: $24.89 | $0.00 |
DisclosureSEC source: 0001519749-21-000004 · edgardoc.xml · derivative · entry 7 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,034 shares Expires 2021-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 22:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 8,034 | $30.00 | $241,020.00 |
DisclosureSEC source: 0001519749-21-000004 · edgardoc.xml · nonDerivative · entry 6 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,128 F1 · kind: The transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 22:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 8,034 | $24.89 | $199,966.26 |
DisclosureSEC source: 0001519749-21-000004 · edgardoc.xml · nonDerivative · entry 5 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 22:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 21,966 | $30.00 | $658,980.00 |
DisclosureSEC source: 0001519749-21-000004 · edgardoc.xml · nonDerivative · entry 4 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,128 F1 · kind: The transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 22:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 21,966 | $24.89 | $546,733.74 |
DisclosureSEC source: 0001519749-21-000004 · edgardoc.xml · nonDerivative · entry 3 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 22:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 28,000 | $30.00 | $840,000.00 |
DisclosureSEC source: 0001519749-21-000004 · edgardoc.xml · nonDerivative · entry 2 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,128 F1 · kind: The transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 22:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 28,000 | $19.47 | $545,160.00 |
DisclosureSEC source: 0001519749-21-000004 · edgardoc.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 20:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 13,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001519749-21-000002 · edgardoc.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,128 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 12:21 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 17,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001519749-20-000011 · edgardoc.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Executive VP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,802 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:43 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 2,218 | $13.04 | $28,922.72 |
DisclosureSEC source: 0001519749-20-000009 · edgardoc.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Executive VP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,949 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 26, 2020 Filed Sep 28, 2020 17:15 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 2,218 | $12.44 | $27,591.92 |
DisclosureSEC source: 0001519749-20-000007 · edgardoc.xml · nonDerivative · entry 3 Hart Jayne B. · CIK 0001519749 · Executive VP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,167 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:15 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 1,664 | $12.44 | $20,700.16 |
DisclosureSEC source: 0001519749-20-000007 · edgardoc.xml · nonDerivative · entry 2 Hart Jayne B. · CIK 0001519749 · Executive VP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,385 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:15 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 2,218 | $12.44 | $27,591.92 |
DisclosureSEC source: 0001519749-20-000007 · edgardoc.xml · nonDerivative · entry 1 Hart Jayne B. · CIK 0001519749 · Executive VP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,049 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.